Released September 18, 2020 | SUGAR LAND
en
In the Pharma/Bio Industry, aseptic fill/finish manufacturing is the aseptic filling of biological drugs or medicines in any form, such as sterile liquid, powder and suspension, in vials, ampoules, bottles syringes and cartridges after the product is produced. As such, the sector is anticipated to play a big role in the manufacture of COVID-19 vaccines.
It is not uncommon that a manufacturer does not have fill/finish capabilities on site. Instead, it is a common practice that the bulk drug substance is made by one manufacturer and shipped to a second site, sometimes a contractor, to fill the final drug product.
Industrial Info is tracking 89 proprietary and contract fill/finish facilities in North America, and 138 related active projects with a total investment value of $4.4 billion.
Click here for a list of facilities, and here for a list of projects. See map below.
It is not uncommon that a manufacturer does not have fill/finish capabilities on site. Instead, it is a common practice that the bulk drug substance is made by one manufacturer and shipped to a second site, sometimes a contractor, to fill the final drug product.
Industrial Info is tracking 89 proprietary and contract fill/finish facilities in North America, and 138 related active projects with a total investment value of $4.4 billion.
Click here for a list of facilities, and here for a list of projects. See map below.
